News|Articles|January 22, 2026
From First-In-Human To Proof-Of-Concept — Quicker, Smarter, Streamlined
Author(s)Quotient Sciences
Dr. Andreas Reichl, Senior Drug Development Consultant, and Dr. Kevin Schaab, Senior Drug Development Consultant, both from Quotient Sciences, present a practical breakdown of how early-phase experts design programs to mitigate risks and efficiently move novel molecules into PoC assessments.
Related Content
Trending on Applied Clinical Trials Online
1
Applying Systems Thinking to the Future of Clinical R&D
2
FDA Finalizes Guidance on Clinical Trial Design for Psychedelic Drug Development
3
Patient Recruitment in Clinical Trials: Why the Industry's Longstanding Approach Is No Longer Fit for Purpose
4
ACT Brief: Local-First Communication Design, RBQM Financial Impact, and First Oral PCSK9 Inhibitor
5